Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial

Core Insights - Anixa Biosciences is advancing its Phase 1 clinical trial for a novel CAR-T therapy targeting ovarian cancer, with treatment for the fifth patient now underway [1][2] - The therapy utilizes a unique approach by targeting the follicle stimulating hormone receptor (FSHR), which is exclusively expressed on ovarian cells, differentiating it from traditional CAR-T therapies [2][3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company also has a vaccine portfolio aimed at preventing triple negative breast cancer and ovarian cancer, as well as other cancers, utilizing technologies that target specific proteins expressed in certain cancers [4] Technology Details - The CAR-T technology developed by Anixa is known as chimeric endocrine receptor T-cell (CER-T) therapy, which is an autologous cell therapy targeting FSHR found on granulosa cells of the ovaries [3] - This innovative approach aims to address challenges faced by traditional CAR-T therapies in treating solid tumors, particularly ovarian cancer [2][3]